Johnson & Johnson (NYSE:JNJ) Shares Sold by Vigilare Wealth Management

Vigilare Wealth Management trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,237 shares of the company’s stock after selling 671 shares during the period. Vigilare Wealth Management’s holdings in Johnson & Johnson were worth $1,011,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Chicago Partners Investment Group LLC boosted its holdings in shares of Johnson & Johnson by 4.5% in the third quarter. Chicago Partners Investment Group LLC now owns 17,436 shares of the company’s stock worth $2,892,000 after buying an additional 744 shares during the period. Phillips Wealth Planners LLC grew its position in Johnson & Johnson by 20.0% during the 3rd quarter. Phillips Wealth Planners LLC now owns 5,006 shares of the company’s stock worth $822,000 after purchasing an additional 833 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Johnson & Johnson by 16.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 53,029 shares of the company’s stock valued at $8,594,000 after purchasing an additional 7,372 shares during the period. Cambiar Investors LLC lifted its holdings in shares of Johnson & Johnson by 10.8% in the third quarter. Cambiar Investors LLC now owns 301,913 shares of the company’s stock valued at $48,928,000 after purchasing an additional 29,391 shares in the last quarter. Finally, Americana Partners LLC grew its holdings in shares of Johnson & Johnson by 0.9% during the third quarter. Americana Partners LLC now owns 76,685 shares of the company’s stock valued at $12,428,000 after buying an additional 683 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Sanford C. Bernstein boosted their target price on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.93.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $160.13 on Friday. The firm has a market capitalization of $385.53 billion, a PE ratio of 23.17, a PEG ratio of 2.84 and a beta of 0.52. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The firm’s fifty day simple moving average is $163.31 and its 200 day simple moving average is $155.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.66 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.10%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is currently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.